Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Philipp M. Roessner"'
Autor:
Giulia Pagano, Iria Fernandez Botana, Marina Wierz, Philipp M. Roessner, Nikolaos Ioannou, Xiangda Zhou, Gheed Al-Hity, Coralie Borne, Ernesto Gargiulo, Susanne Gonder, Bin Qu, Basile Stamatopoulos, Alan G. Ramsay, Martina Seiffert, Anne Largeot, Etienne Moussay, Jerome Paggetti
Publikováno v:
Haematologica, Vol 108, Iss 11 (2023)
Chronic lymphocytic leukemia (CLL) cells are highly dependent on interactions with the immunosuppressive tumor microenvironment (TME) for survival and proliferation. In the search for novel treatments, pro-inflammatory cytokines have emerged as candi
Externí odkaz:
https://doaj.org/article/f29683a86d924b2e8fdf058bdcf1c6eb
Autor:
Sebastian Faehling, Mariana Coelho, Alessia Floerchinger, Christof Schneider, Stephan Stilgenbauer, Peter Lichter, Martina Seiffert, Philipp M. Roessner
Publikováno v:
HemaSphere, Vol 7, Iss 3, p e840 (2023)
Chronic lymphocytic leukemia (CLL) is a common and incurable B-cell malignancy. Recent therapeutic approaches that target the B-cell receptor signaling pathway include inhibition of phosphatidylinositol-3-kinase (PI3K). The PI3K isoform delta is cons
Externí odkaz:
https://doaj.org/article/e31f1ca7f2774fc2bea8e1bd8ee35adf
Autor:
Justyna A. Wierzbinska, Reka Toth, Naveed Ishaque, Karsten Rippe, Jan-Philipp Mallm, Lara C. Klett, Daniel Mertens, Thorsten Zenz, Thomas Hielscher, Marc Seifert, Ralf Küppers, Yassen Assenov, Pavlo Lutsik, Stephan Stilgenbauer, Philipp M. Roessner, Martina Seiffert, John Byrd, Christopher C. Oakes, Christoph Plass, Daniel B. Lipka
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-19 (2020)
Abstract Background In cancer, normal epigenetic patterns are disturbed and contribute to gene expression changes, disease onset, and progression. The cancer epigenome is composed of the epigenetic patterns present in the tumor-initiating cell at the
Externí odkaz:
https://doaj.org/article/07bff21ec86d48ca9abc2144570ae521
Autor:
Ebru Aydin, Sebastian Faehling, Mariam Saleh, Laura Llaó Cid, Martina Seiffert, Philipp M. Roessner
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Phosphoinositide 3-kinases (PI3Ks) and their downstream proteins constitute a signaling pathway that is involved in both normal cell growth and malignant transformation of cells. Under physiological conditions, PI3K signaling regulates various cellul
Externí odkaz:
https://doaj.org/article/6b5128b3cc9f4a7990b045db09c24bcd
Autor:
Bola S. Hanna, Haniyeh Yazdanparast, Yasmin Demerdash, Philipp M. Roessner, Ralph Schulz, Peter Lichter, Stephan Stilgenbauer, Martina Seiffert
Publikováno v:
Haematologica, Vol 106, Iss 4 (2020)
Ibrutinib is a bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of multiple B-cell malignancies, including chronic lymphocytic leukemia (CLL). In addition to blocking B-cell receptor signaling and chemokine receptor-mediated path
Externí odkaz:
https://doaj.org/article/e1c4b619ea8642018da18ce254fffb71
Publikováno v:
Cancers, Vol 13, Iss 8, p 1899 (2021)
Indoleamine-2,3-dioxygenase 1 (IDO1), a tryptophan (Trp)-catabolizing enzyme producing metabolites such as kynurenine (Kyn), is expressed by myeloid-derived suppressor cells (MDSCs) and associated with cancer immune escape. IDO1-expressing monocytic
Externí odkaz:
https://doaj.org/article/e086228d5731422da2e02988560d0e9e
Autor:
Sascha Dietrich, Irene Gil-Farina, Selcen Öztürk, Marc Zapatka, Peter Lichter, Lavinia Arseni, Manfred Schmidt, Bola S. Hanna, Philipp M. Roessner, Anna Jauch, Stephan Stilgenbauer, Peter-Martin Bruch, Saira Afzal, Yashna Paul, Martina Seiffert, Verena Kalter
Publikováno v:
Leukemia
Chronic lymphocytic leukemia (CLL) is a B-cell malignancy mainly occurring at an advanced age with no single major genetic driver. Transgenic expression of TCL1 in B cells leads after a long latency to a CLL-like disease in aged Eµ-TCL1 mice suggest
Autor:
Ana Izcue, Marie Bordas, Bola S. Hanna, Vicente Chapaprieta, Martina Seiffert, Laura Llaó-Cid, Stephan Stilgenbauer, Philipp M. Roessner, Sascha Dietrich, Selcen Öztürk, José I. Martín-Subero, Tobias Roider, Dolors Colomer
Publikováno v:
Leukemia
Leukemia : the Journal of Normal and Malignant Hemopoiese ; Official Journal of the Leukemia Research Fund U.K.
Leukemia : normal and malignant hemopoiesis 35(11), 3152-3162 (2021). doi:10.1038/s41375-021-01198-1
Leukemia : the Journal of Normal and Malignant Hemopoiese ; Official Journal of the Leukemia Research Fund U.K.
Leukemia : normal and malignant hemopoiesis 35(11), 3152-3162 (2021). doi:10.1038/s41375-021-01198-1
Leukemia : normal and malignant hemopoiesis 35(11), 3152-3162 (2021). doi:10.1038/s41375-021-01198-1
Published by Springer Nature, London
Published by Springer Nature, London
Autor:
Christoph Schifflers, Philipp M. Roessner, Marit Krötschel, Fabian Kilpert, Stephan Stilgenbauer, Leopold Sellner, Ekaterina Lupar, Ana Izcue, Sascha Dietrich, Marie Bordas, Ann-Christin Gaupel, Lavinia Arseni, Sebastian J. Arnold, Tobias Roider, Martina Seiffert, Laura Llaó Cid, Dolors Colomer, Peter Lichter
Publikováno v:
Leukemia
Roessner, P M, Llaó Cid, L, Lupar, E, Roider, T, Bordas, M, SCHIFFLERS, C, Arseni, L, Gaupel, A-C, Kilpert, F, Krötschel, M, Arnold, S J, Sellner, L, Colomer, D, Stilgenbauer, S, Dietrich, S, Lichter, P, Izcue, A & Seiffert, M 2021, ' EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4 + T cells in chronic lymphocytic leukemia ', Leukemia, vol. 35, no. 8, pp. 2311-2324 . https://doi.org/10.1038/s41375-021-01136-1
Leukemia : normal and malignant hemopoiesis 35(8), 2311-2324 (2021). doi:10.1038/s41375-021-01136-1
Leukemia : the Journal of Normal and Malignant Hemopoiese ; Official Journal of the Leukemia Research Fund U.K.
Roessner, P M, Llaó Cid, L, Lupar, E, Roider, T, Bordas, M, SCHIFFLERS, C, Arseni, L, Gaupel, A-C, Kilpert, F, Krötschel, M, Arnold, S J, Sellner, L, Colomer, D, Stilgenbauer, S, Dietrich, S, Lichter, P, Izcue, A & Seiffert, M 2021, ' EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4 + T cells in chronic lymphocytic leukemia ', Leukemia, vol. 35, no. 8, pp. 2311-2324 . https://doi.org/10.1038/s41375-021-01136-1
Leukemia : normal and malignant hemopoiesis 35(8), 2311-2324 (2021). doi:10.1038/s41375-021-01136-1
Leukemia : the Journal of Normal and Malignant Hemopoiese ; Official Journal of the Leukemia Research Fund U.K.
Leukemia : normal and malignant hemopoiesis 35(8), 2311-2324 (2021). doi:10.1038/s41375-021-01136-1
Published by Springer Nature, London
Published by Springer Nature, London
Autor:
Martina Seiffert, Stephan Stilgenbauer, Ralph Schulz, Peter Lichter, Philipp M. Roessner, Haniyeh Yazdanparast, Yasmin Demerdash, Bola S. Hanna
Publikováno v:
Haematologica
Ibrutinib is a bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of multiple B-cell malignancies, including chronic lymphocytic leukemia (CLL). In addition to blocking B-cell receptor signaling and chemokine receptor-mediated path